Up-To-Date Perspectives for Hyperuricemia, Cardiorenal Influence and Urate-Lowering Therapy (ULT)

Hiroshi Bando^1,2*
1Medical Research/Tokushima University, Tokushima, Japan
²Integrative Medicine Japan (IMJ), Shikoku Island division, Tokushima, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 26 March 2021; Accepted date: 17 April 2021; Published date: 27 April 2021

Citation: Bando H. Up-To-Date Perspectives for Hyperuricemia, Cardiorenal Influence and Urate-Lowering Therapy (ULT). Diab Res Open Access. 2021 April 27;3(1):16-19.

Copyright © 2021 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: Hyperuricemia, Urate-Lowering Therapy, Selective Urate Reabsorption Inhibitor, Chronic Kidney Disease, Preventing Early Renal Loss in Diabetes, American College of Rheumatology

Abbreviations: ULT: Urate-Lowering Therapy; SURI: Selective Urate Reabsorption Inhibitor; CKD: Chronic Kidney Disease; PERL: Preventing Early Renal Loss in Diabetes; ACR: American College of Rheumatology

Abstract

Hyperuricemia is a clinical important problem and its prevalence has been increased. Latest topics are described. The guideline adequately managing gout was published from American College of Rheumatology (ACR). Various optimal uses of urate-lowering therapy (ULT) were presented. The cardiorenal effects of hyperuricemia have been investigated for years. Regarding the patients on chronic kidney disease (CKD) and high risk of progression, ULT with allopurinol did not show the decline in eGFR compared to the control. Recently, dotinurad that is a new selective urate reabsorption inhibitor (SURI) would be applied to medical practice. Low-dose dotinurad showed satisfactory pharmacological efficacy.